401 related articles for article (PubMed ID: 24052547)
21. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
22. Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY; Schlag PA; Karwowska SM; Manohar CF; Truong HM; Longshore JW; Zhang G
PLoS One; 2023; 18(12):e0292251. PubMed ID: 38096164
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.
Schmidt J; Gong S; Marafioti T; Mankel B; Gonzalez-Farre B; Balagué O; Mozos A; Cabeçadas J; van der Walt J; Hoehn D; Rosenwald A; Ott G; Dojcinov S; Egan C; Nadeu F; Ramis-Zaldívar JE; Clot G; Bárcena C; Pérez-Alonso V; Endris V; Penzel R; Lome-Maldonado C; Bonzheim I; Fend F; Campo E; Jaffe ES; Salaverria I; Quintanilla-Martinez L
Blood; 2016 Aug; 128(8):1101-11. PubMed ID: 27257180
[TBL] [Abstract][Full Text] [Related]
24. CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.
Xian RR; Xie Y; Haley LM; Yonescu R; Pallavajjala A; Pittaluga S; Jaffe ES; Duffield AS; McCall CM; Gheith SMF; Gocke CD
Blood Cancer J; 2020 Jun; 10(6):69. PubMed ID: 32555149
[TBL] [Abstract][Full Text] [Related]
25. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
[TBL] [Abstract][Full Text] [Related]
26. Mutations of
Schmidt J; Ramis-Zaldivar JE; Nadeu F; Gonzalez-Farre B; Navarro A; Egan C; Montes-Mojarro IA; Marafioti T; Cabeçadas J; van der Walt J; Dojcinov S; Rosenwald A; Ott G; Bonzheim I; Fend F; Campo E; Jaffe ES; Salaverria I; Quintanilla-Martinez L
Blood; 2017 Jul; 130(3):323-327. PubMed ID: 28533310
[TBL] [Abstract][Full Text] [Related]
27. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
Larrea E; Fernandez-Mercado M; Guerra-Assunção JA; Wang J; Goicoechea I; Gaafar A; Ceberio I; Lobo C; Okosun J; Enright AJ; Fitzgibbon J; Lawrie CH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233721
[TBL] [Abstract][Full Text] [Related]
28. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
[TBL] [Abstract][Full Text] [Related]
29. B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.
Slot LM; Hoogeboom R; Smit LA; Wormhoudt TA; Biemond BJ; Oud ME; Schilder-Tol EJ; Mulder AB; Jongejan A; van Kampen AH; Kluin PM; Guikema JE; Bende RJ; van Noesel CJ
Am J Pathol; 2016 Dec; 186(12):3273-3284. PubMed ID: 27750045
[TBL] [Abstract][Full Text] [Related]
30. Deregulation of H3K27 methylation in cancer.
Martinez-Garcia E; Licht JD
Nat Genet; 2010 Feb; 42(2):100-1. PubMed ID: 20104248
[TBL] [Abstract][Full Text] [Related]
31. Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?
Amengual JE; O'Connor OA
Clin Cancer Res; 2014 Jun; 20(12):3047-9. PubMed ID: 24857928
[TBL] [Abstract][Full Text] [Related]
32. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
[TBL] [Abstract][Full Text] [Related]
33. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
Bouska A; Zhang W; Gong Q; Iqbal J; Scuto A; Vose J; Ludvigsen M; Fu K; Weisenburger DD; Greiner TC; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Delabie J; Jaffe ES; Braziel RM; Connors JM; Wu CI; Staudt LM; D'Amore F; McKeithan TW; Chan WC
Leukemia; 2017 Jan; 31(1):83-91. PubMed ID: 27389057
[TBL] [Abstract][Full Text] [Related]
34. EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.
Szumera-CieĆkiewicz A; Poleszczuk J; Paszkiewicz-Kozik E; Rymkiewicz G; SokÓŁ K; Borysiuk A; Kotarska M; Owczarek D; Kawecka M; Pytlak B; Walewski J; Prochorec-Sobieszek M
Anticancer Res; 2020 Dec; 40(12):6685-6697. PubMed ID: 33288562
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
36. [EZH inhibitors in lymphoma therapy].
Ishitsuka K
Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
[TBL] [Abstract][Full Text] [Related]
38. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
Martínez-Laperche C; Sanz-Villanueva L; Díaz Crespo FJ; Muñiz P; Martín Rojas R; Carbonell D; Chicano M; Suárez-González J; Menárguez J; Kwon M; Diez Martín JL; Buño I; Bastos Oreiro M
BMC Cancer; 2022 Sep; 22(1):982. PubMed ID: 36104682
[TBL] [Abstract][Full Text] [Related]
39. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.
Nann D; Ramis-Zaldivar JE; Müller I; Gonzalez-Farre B; Schmidt J; Egan C; Salmeron-Villalobos J; Clot G; Mattern S; Otto F; Mankel B; Colomer D; Balagué O; Szablewski V; Lome-Maldonado C; Leoncini L; Dojcinov S; Chott A; Copie-Bergman C; Bonzheim I; Fend F; Jaffe ES; Campo E; Salaverria I; Quintanilla-Martinez L
Blood Adv; 2020 Nov; 4(22):5652-5665. PubMed ID: 33211828
[TBL] [Abstract][Full Text] [Related]
40. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin W; Teater M; Meydan C; Hoehn KB; Phillip JM; Soshnev AA; Venturutti L; Rivas MA; Calvo-Fernández MT; Gutierrez J; Camarillo JM; Takata K; Tarte K; Kelleher NL; Steidl C; Mason CE; Elemento O; Allis CD; Kleinstein SH; Melnick AM
Cancer Cell; 2020 May; 37(5):655-673.e11. PubMed ID: 32396861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
